Sage Says Brexanolone's SRSE Result Doesn't Mean PPD Studies Will Fail

The Phase III study for brexanolone in super-refractory status epilepticus did not meet its primary endpoint, but Sage is optimistic about the drug's prospects in postpartum depression and its earlier-stage SAGE-217.